IMVT News

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune disea...

What are the projected timelines for regulatory approval, commercialization, and reimbursement for batoclimab, and how could these factors impact long‑term earnings forecasts? What comparative advantages does batoclimab have over existing or pipeline therapies for uncontrolled Graves' disease, and how might this affect market share potential? How will the six‑month off‑treatment remission data for batoclimab influence IMVT's valuation and short‑term stock momentum?

Clinical trials

about 5 hours ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune disea...

How does batoclimab's efficacy, safety, and durability data compare to existing therapies and competing pipeline candidates for Graves' disease? How large is the addressable market for uncontrolled Graves' disease and what market share could Immunovant realistically capture with a treatment‑free remission therapy? What is the anticipated regulatory timeline and likelihood of FDA approval for batoclimab following these six‑month off‑treatment remission results?

Clinical trials

about 5 hours ago

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

(NASDAQ:IMVT) NEW YORK and NEW ORLEANS, Aug. 29, 2025 /PRNewswire/ -- The law firm of Kahn Swick & Foti, LLC ("KSF") has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ("Immunova...

How will the market perception of Immunovant’s fiduciary compliance risk influence short‑term liquidity and trading volume for IMVT? Could the investigation lead to changes in the company's leadership or governance structure, and what impact might that have on operational continuity? What potential financial penalties or legal liabilities could arise from the investigation and how might they affect Immunovant's balance sheet?

Lawsuits

5 days ago

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

What is the credibility and track record of the Schall Law Firm in handling similar securities fraud cases, and how might that influence settlement outcomes? How likely is the investigation to result in material adverse disclosures or regulatory actions that could affect IMVT's share price? What are the specific allegations and potential liabilities facing Immunovant, Inc. in the fraud investigation?

Lawsuits

7 days ago

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigati...

What is the expected timeline for the investigation and any potential disclosures to the SEC? Could this investigation trigger a downgrade by rating agencies or affect the company’s credit facilities? How are institutional investors and large shareholders reacting to this announcement?

Lawsuits

21 days ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today repo...

What is the market's reaction to this earnings release, and are there any notable changes in analyst sentiment or coverage? Are there any regulatory or reimbursement risks highlighted that could impact the commercialization timeline of its pipeline candidates? What is the status of the company's cash and liquidity position, and are there any upcoming financing needs or dilution concerns?

Earnings

23 days ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick &amp; Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT